Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3939121rdf:typepubmed:Citationlld:pubmed
pubmed-article:3939121lifeskim:mentionsumls-concept:C0003232lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C0033809lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C0080194lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C0028365lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:3939121lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:3939121pubmed:issue4lld:pubmed
pubmed-article:3939121pubmed:dateCreated1986-8-8lld:pubmed
pubmed-article:3939121pubmed:abstractTextThe in vitro susceptibility of 54 multiple-resistant strains of Pseudomonas aeruginosa to 16 antipseudomonal agents were determined. The majority of these organisms were also beta-lactamase-producing strains. Norfloxacin, N-formimidoyl-thienamycin and aztreonam showed the best antipseudomonal activity, with minimum inhibitory concentrations for 90% of isolates (MIC90) of 2, 8, and 8 mg/l respectively. Of the aminoglycosides, only amikacin (MIC90 = 32 mg/l) showed satisfactory activity, whereas among beta-lactam antibiotics, cefotaxime, ceftriaxone and moxalactam (MIC90 = 32 mg/l) were more active than cefoperazone (MIC90 = 128 mg/l), cefsulodin (MIC90 = 128 mg/l), piperacillin (MIC90 = 512 mg/l) and azlocillin (MIC90 = 1024 mg/l). A synergistic or partially synergistic interaction (fractional inhibitory concentration index less than 1) was demonstrated in vitro against 37% of the strains when N-formimidoyl-thienamycin was combined with norfloxacin.lld:pubmed
pubmed-article:3939121pubmed:languageenglld:pubmed
pubmed-article:3939121pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:citationSubsetIMlld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3939121pubmed:statusMEDLINElld:pubmed
pubmed-article:3939121pubmed:issn0378-6501lld:pubmed
pubmed-article:3939121pubmed:authorpubmed-author:SerraPPlld:pubmed
pubmed-article:3939121pubmed:authorpubmed-author:MartinoPPlld:pubmed
pubmed-article:3939121pubmed:authorpubmed-author:BrandimarteCClld:pubmed
pubmed-article:3939121pubmed:authorpubmed-author:ValentiFFlld:pubmed
pubmed-article:3939121pubmed:authorpubmed-author:VendittiMMlld:pubmed
pubmed-article:3939121pubmed:issnTypePrintlld:pubmed
pubmed-article:3939121pubmed:volume11lld:pubmed
pubmed-article:3939121pubmed:ownerNLMlld:pubmed
pubmed-article:3939121pubmed:authorsCompleteYlld:pubmed
pubmed-article:3939121pubmed:pagination247-51lld:pubmed
pubmed-article:3939121pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:meshHeadingpubmed-meshheading:3939121-...lld:pubmed
pubmed-article:3939121pubmed:year1985lld:pubmed
pubmed-article:3939121pubmed:articleTitleN-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics.lld:pubmed
pubmed-article:3939121pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3939121pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3939121pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3939121lld:pubmed